10601 results for 'EGF Receptor Inhibitors'

Quick Facts About AtezolizumabWhat is Atezolizumab?Atezolizumab is an anti-PD-L1 monoclonal antibody used in immunotherapy to treat various cancers by enhancing the immune system's abili

Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab

The most abundant immunosuppressive molecule in a solid tumour is not a protein. It is adenosine — a metabolite, produced from ATP in two enzymatic steps, at concentrations orders of magnitude above

Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance

Targeting USP22: A New Approach to Enhance Anticancer Immunity Introduction In the ever-evolving landscape of cancer research, the intricate relationship between immune e

Cancer immunotherapy has revolutionized oncology, offering powerful new ways to treat various malignancies by harnessing the body's own immune system. Central to this success are immune checkpoint inh

Immunology · CytokinesIFN-gamma: Signalling, Function and Roles in Inflammation, Cancer and AutoimmunityInterferon gamma is the sole type II interferon and one of the most consequential cytokines in i

Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne

CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, plays a pivotal role in regulating immune responses, particularly in activating antigen-presenting cells (APCs) an

Quick Facts About RamucirumabWhat is Ramucirumab?Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting angiogenesis, a pro

Protein Analysis · ProtocolsWestern Blot Sample Preparation: A Practical GuideMost failed Western blots fail before the gel is loaded. Lysis buffer choice, inhibitor selection, accurate protein quanti

Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b

Cell Biology · Protein DegradationThe Autophagy Pathway: Mechanism, Regulation and How to Measure ItAutophagy is the cell’s route for degrading and recycling its own contents — damaged organelles, agg

Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer (

Immunology · Flow CytometryT Cell Immunophenotyping: Markers, Subsets and Panel DesignImmunophenotyping identifies cell populations by the proteins on their surface. For T cells that means resolving n

Quick Facts About EnapotamabWhat is Enapotamab?Enapotamab is an experimental antibody-drug conjugate (ADC) developed to target tumor cells selectively, offering new hope in cancer treatm

Immunology · Antibody BiologyAntibody Light Chains, Heavy Chains, Constant Regions & Tumour-Associated AntigensAn antibody’s specificity comes from its variable domains and its biological effect comes

Harnessing the immune system to fight cancer has become a pivotal strategy in modern oncology. A key component in this fight is CD27, a receptor that plays a crucial role in T-cell activa

What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c